Context-dependent functions of pattern recognition receptors in cancer

SM Man, BJ Jenkins - Nature Reviews Cancer, 2022 - nature.com
The immune system plays a critical role in sha** all facets of cancer, from the early
initiation stage through to metastatic disease and resistance to therapy. Our understanding …

Radiogenomics in renal cancer management—current evidence and future prospects

M Ferro, G Musi, M Marchioni, M Maggi… - International journal of …, 2023 - mdpi.com
Renal cancer management is challenging from diagnosis to treatment and follow-up. In
cases of small renal masses and cystic lesions the differential diagnosis of benign or …

[HTML][HTML] New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia

K Trpkov, O Hes, SR Williamson, AJ Adeniran… - Modern Pathology, 2021 - Elsevier
Abstract The Genitourinary Pathology Society (GUPS) reviewed recent advances in renal
neoplasia, particularly post-2016 World Health Organization (WHO) classification, to provide …

Interferon signaling promotes tolerance to chromosomal instability during metastatic evolution in renal cancer

L Perelli, F Carbone, L Zhang, JK Huang, C Le… - Nature Cancer, 2023 - nature.com
Molecular routes to metastatic dissemination are critical determinants of aggressive cancers.
Through in vivo CRISPR–Cas9 genome editing, we generated somatic mosaic genetically …

Proteogenomic characterization of MiT family translocation renal cell carcinoma

Y Qu, X Wu, A Anwaier, J Feng, W Xu, X Pei… - Nature …, 2022 - nature.com
Microphthalmia transcription factor (MiT) family translocation renal cell carcinoma (tRCC) is
a rare type of kidney cancer, which is not well characterized. Here we show the …

[HTML][HTML] The impact of hypoxia on tumor-mediated bypassing anti-PD-(L) 1 therapy

K Mortezaee, J Majidpoor, E Kharazinejad - Biomedicine & …, 2023 - Elsevier
Extending the durability of response is the current focus in cancer immunotherapy with
immune checkpoint inhibitors (ICIs). However, factors like non-immunogenic tumor …

Proteogenomic characterization of skull-base chordoma

Q Zhang, Z Xu, R Han, Y Wang, Z Ye, J Zhu… - Nature …, 2024 - nature.com
Skull-base chordoma is a rare, aggressive bone cancer with a high recurrence rate. Despite
advances in genomic studies, its molecular characteristics and effective therapies remain …

SMARCB1-deficient cancers: novel molecular insights and therapeutic vulnerabilities

GW Cooper, AL Hong - Cancers, 2022 - mdpi.com
Simple Summary Loss of SMARCB1 has been identified as the sole mutation in a number of
rare pediatric and adult cancers, most of which have a poor prognosis despite intensive …

Clinico-pathological implications of the 2022 WHO Renal Cell Carcinoma classification

M Rizzo, A Caliò, M Brunelli, G Pezzicoli… - Cancer treatment …, 2023 - Elsevier
The new WHO classification of urogenital tumours published in 2022, contains significant
revisions upon the previous 2016 version regarding Renal Cell Carcinoma (RCC). While the …

Checkpoint Immunotherapy in Pediatrics: Here, Gone, and Back Again.

AH Long, DA Morgenstern, A Leruste… - American Society of …, 2022 - europepmc.org
The role of immune checkpoint inhibitors (ICIs) in the treatment of pediatric cancers
continues to evolve. Such therapies function by augmenting existing antitumor T-cell …